These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Clinical observations on a new cardiotonic drug (Talusin)]. Amoroso A; Ghiara F Minerva Med; 1966 Oct; 57(81):3301-4. PubMed ID: 5955198 [No Abstract] [Full Text] [Related]
5. [Therapy of the slightly damaged heart with a cardiotonic agent]. Guttmann W Med Welt; 1969 Sep; 37():2035-7. PubMed ID: 5389269 [No Abstract] [Full Text] [Related]
6. [Influencing the cardiotonic effect of proscillaridin by verapamil]. Manns KJ Med Klin; 1969 Oct; 64(44):2022-7. PubMed ID: 5370836 [No Abstract] [Full Text] [Related]
7. [Pharmacological approach to the rational use of cardiotonic heterosides]. Tillement JP; Albengres E Coeur Med Interne; 1977; 16(2):239-48. PubMed ID: 891123 [No Abstract] [Full Text] [Related]
8. [Cardiotonic action of cardiac glycosides and lipid metabolism (literature survey)]. Chekman IS; Poliakova IF Vrach Delo; 1975 Nov; (11):5-10. PubMed ID: 1199054 [No Abstract] [Full Text] [Related]
9. [Recent aspects of therapy with cardiac glycosides]. Bayer O; Jost F Dtsch Med J; 1970 May; 21(10):675-6 passim. PubMed ID: 5523167 [No Abstract] [Full Text] [Related]
10. [Cardiac glycosides]. Pankratov AB Med Sestra; 1978 Mar; 37(3):34-40. PubMed ID: 247167 [No Abstract] [Full Text] [Related]
11. [Oral heart and circulatory therapy with a new combination glycoside preparation]. Fischer T Ther Ggw; 1966 Feb; 105(2):239-49. PubMed ID: 5915867 [No Abstract] [Full Text] [Related]
12. [Experience in the use of cardiac glycosides in children with heart diseases]. Landa NM; Shcherbatova EI Vopr Okhr Materin Det; 1971 Jun; 16(6):69-73. PubMed ID: 5112039 [No Abstract] [Full Text] [Related]
13. [Current problems of pharmacotherapy. VII. Aspects of an ambulatory glycoside therapy]. Herling M; Oehme P; Parsi RA Dtsch Gesundheitsw; 1969 Dec; 24(49):2305-9. PubMed ID: 5405889 [No Abstract] [Full Text] [Related]
14. [Proscillaridin A in the therapy of decompensated heart diseases]. Vigna L; Mollica G Minerva Cardioangiol; 1968 Oct; 16(10):987-90. PubMed ID: 5750066 [No Abstract] [Full Text] [Related]
15. [New aspects of glycoside therapy]. Klepzig H Z Allgemeinmed; 1972 Mar; 48(9):418-21. PubMed ID: 4402437 [No Abstract] [Full Text] [Related]
16. [The significance of phase analysis in the pharmacotherapeutic control of the effect of cardiac glycosides]. Belostochnaia NG Ter Arkh; 1967 Apr; 39(4):65-7. PubMed ID: 5610908 [No Abstract] [Full Text] [Related]
17. [Are cardiac glycosides recommended following an attack of encephalomalacia?]. Aschenbrenner R Dtsch Med Wochenschr; 1968 Jan; 93(1):48. PubMed ID: 5635032 [No Abstract] [Full Text] [Related]
18. [Structure and effect of cardiac glycosides from the clinical viewpoint]. Sundermann A; Fiehring H Dtsch Gesundheitsw; 1967 May; 22(20):919-23. PubMed ID: 5600800 [No Abstract] [Full Text] [Related]
19. [Problems of the therapy with cardiac glycosides in surgery]. Rittmeyer P Z Prakt Anasth; 1970 Dec; 5(6):373-9. PubMed ID: 4256250 [No Abstract] [Full Text] [Related]
20. [Cardioactive therapy in the elderly]. Macchione C G Gerontol; 1972 May; 20(5):434-42. PubMed ID: 5052155 [No Abstract] [Full Text] [Related] [Next] [New Search]